AN2 Therapeutics gets FDA clearance for Phase 2 epetraborole trial in polycythemia vera
ANTX•AN2 Therapeutics received FDA clearance to proceed with a Phase 2 trial of oral epetraborole for polycythemia vera. The global trial is expected to begin in the fourth quarter of 2026, with regulatory clearance secured in all planned jurisdictions.
1. Trial clearance
AN2 Therapeutics received FDA clearance to proceed with a global Phase 2 trial of oral epetraborole for polycythemia vera. The trial is expected to begin in the fourth quarter of 2026, and regulatory clearance has been secured in all planned jurisdictions.
